THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 94 filers reported holding THERAVANCE BIOPHARMA INC in Q3 2018. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $142,438 | -35.0% | 16,505 | -22.1% | 0.00% | – |
| Q2 2023 | $219,265 | +28.0% | 21,185 | +34.2% | 0.00% | – |
| Q1 2023 | $171,267 | -27.7% | 15,785 | +70.3% | 0.00% | – |
| Q4 2018 | $237,000 | -22.0% | 9,270 | -0.4% | 0.00% | – |
| Q3 2018 | $304,000 | +42.1% | 9,310 | -1.5% | 0.00% | – |
| Q2 2018 | $214,000 | – | 9,450 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Chescapmanager LLC | 1,134,718 | $23,160,000 | 2.47% |
| Baupost Group | 8,735,168 | $178,285,000 | 1.42% |
| Orbimed Advisors | 6,219,110 | $126,932,000 | 1.19% |
| CM Management, LLC | 50,000 | $1,021,000 | 0.76% |
| Tekla Capital Management LLC | 456,296 | $9,313,000 | 0.32% |
| Rock Springs Capital Management LP | 682,600 | $13,932,000 | 0.30% |
| Virtus ETF Advisers LLC | 32,871 | $671,000 | 0.28% |
| Cormorant Asset Management, LP | 550,000 | $11,226,000 | 0.25% |
| DAFNA Capital Management LLC | 41,165 | $840,000 | 0.20% |
| PEREGRINE CAPITAL MANAGEMENT LLC | 484,206 | $9,883,000 | 0.18% |